9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
August 2006 in “JNCI Journal of the National Cancer Institute” 14 citations
,
June 1995 in “The Journal of Clinical Endocrinology and Metabolism” March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
July 2025 in “International Journal of Pharmacy and Pharmaceutical Science” Herbal medicine may help treat breast cancer and improve quality of life.
May 2025 in “Journal of the ASEAN Federation of Endocrine Societies” Thorough evaluation is crucial for postmenopausal women with virilization to detect rare ovarian tumors.
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
Tadalafil may reduce the risk of major heart events and blood clots in men with urinary symptoms.
7 citations
,
May 2022 in “Indonesian Journal of Science and Technology” Compounds from Etlingera alba may help treat Triple Negative Breast Cancer.
June 2018 in “The Journal of Sexual Medicine” Finasteride helps female-pattern hair loss.
35 citations
,
July 2022 in “Frontiers in Integrative Neuroscience” Formononetin may help protect the brain and treat neurological diseases.
January 2020 in “Indian Journal of Pharmaceutical Sciences” Kuntai capsules combined with nilestriol tablets effectively reduce perimenopausal symptoms and improve hormone levels.
April 2018 in “Journal of Investigative Dermatology” Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
October 2023 in “Journal of the Endocrine Society” A woman's ovarian fibroma caused high testosterone levels, which normalized after surgery.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
January 1994 in “JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS” Testosterone and fleece-flower root affect mouse hair growth.
2 citations
,
October 2021 in “Exploration of targeted anti-tumor therapy” Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.
April 2026 in “Preprints.org” Cold Atmospheric Plasma shows promise in treating aggressive breast cancer by targeting cancer cells while sparing normal tissue.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
37 citations
,
February 2013 in “Maturitas” Testosterone therapy is beneficial for women's health and does not cause masculinization or liver damage, and it protects the heart and breasts.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
72 citations
,
January 2004 in “Dermatology” Finasteride can slow hair loss and promote growth in postmenopausal women.
1 citations
,
February 2025 in “Supportive Care in Cancer” Safe treatments like minoxidil and spironolactone can help manage hair loss in breast cancer patients without increasing cancer risk.
February 2020 in “Definitions” March 2021 in “Arrow - TU Dublin (Technological University Dublin)” The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.